tgf-β2 genscript z03429 Search Results


pd l1  (Sino Biological)
91
Sino Biological pd l1
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd l1/product/Sino Biological
Average 91 stars, based on 1 article reviews
pd l1 - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
tgf-β2 z03429  (GenScript corporation)
90
GenScript corporation tgf-β2 z03429
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Tgf β2 Z03429, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tgf-β2 z03429/product/GenScript corporation
Average 90 stars, based on 1 article reviews
tgf-β2 z03429 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tgf-β2  (GenScript corporation)
90
GenScript corporation tgf-β2
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Tgf β2, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tgf-β2/product/GenScript corporation
Average 90 stars, based on 1 article reviews
tgf-β2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
96 well flat-bottom plates 9018  (Corning Life Sciences)
90
Corning Life Sciences 96 well flat-bottom plates 9018
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
96 Well Flat Bottom Plates 9018, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/96 well flat-bottom plates 9018/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
96 well flat-bottom plates 9018 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tgf-β1  (GenScript corporation)
90
GenScript corporation tgf-β1
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Tgf β1, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tgf-β1/product/GenScript corporation
Average 90 stars, based on 1 article reviews
tgf-β1 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cst 12640 rabbit human  (Cell Signaling Technology Inc)
98
Cell Signaling Technology Inc cst 12640 rabbit human
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Cst 12640 Rabbit Human, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cst 12640 rabbit human/product/Cell Signaling Technology Inc
Average 98 stars, based on 1 article reviews
cst 12640 rabbit human - by Bioz Stars, 2026-02
98/100 stars
  Buy from Supplier
pkm1 d30g6 cst 7067 rabbit human  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc pkm1 d30g6 cst 7067 rabbit human
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Pkm1 D30g6 Cst 7067 Rabbit Human, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pkm1 d30g6 cst 7067 rabbit human/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
pkm1 d30g6 cst 7067 rabbit human - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
pyruvate dehydrogenase c54g1 cst 3205 rabbit human  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc pyruvate dehydrogenase c54g1 cst 3205 rabbit human
The basic characteristics of YM101. a The structure of YM101. YM101 contains two <t>anti-PD-L1</t> regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1
Pyruvate Dehydrogenase C54g1 Cst 3205 Rabbit Human, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pyruvate dehydrogenase c54g1 cst 3205 rabbit human/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
pyruvate dehydrogenase c54g1 cst 3205 rabbit human - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


The basic characteristics of YM101. a The structure of YM101. YM101 contains two anti-PD-L1 regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: The basic characteristics of YM101. a The structure of YM101. YM101 contains two anti-PD-L1 regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. e – g The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. h – j The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: SDS Page, Binding Assay, Incubation, Enzyme-linked Immunosorbent Assay

The antagonistic effect of YM101 on TGF-β signaling pathway and epithelial-mesenchymal transition in cancer cells. a , b Smad luciferase reporter assay to measure the effect of YM101 on canonical TGF-β signaling. In the presence of TGF-β1 (10 ng/ml), Smad-luc-transfected NF639 and 4T1 cells were incubated with YM101 or controls for 24 h. Then, luminescence was detected. c , d Transwell migration and invasion assays to determine the effect of YM101 on TGF-β-regulated cell movement in cancer cells. e Western blotting assays to measure the effect of YM101 on TGF-β-mediated epithelial-mesenchymal transition in cancer cells. After treatment with TGF-β1 (10 ng/ml) plus antibodies for 4 days, epithelial-mesenchymal transition-associated markers were detected. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: The antagonistic effect of YM101 on TGF-β signaling pathway and epithelial-mesenchymal transition in cancer cells. a , b Smad luciferase reporter assay to measure the effect of YM101 on canonical TGF-β signaling. In the presence of TGF-β1 (10 ng/ml), Smad-luc-transfected NF639 and 4T1 cells were incubated with YM101 or controls for 24 h. Then, luminescence was detected. c , d Transwell migration and invasion assays to determine the effect of YM101 on TGF-β-regulated cell movement in cancer cells. e Western blotting assays to measure the effect of YM101 on TGF-β-mediated epithelial-mesenchymal transition in cancer cells. After treatment with TGF-β1 (10 ng/ml) plus antibodies for 4 days, epithelial-mesenchymal transition-associated markers were detected. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Luciferase, Reporter Assay, Transfection, Incubation, Migration, Western Blot

YM101 counteracted TGF-β1-induced the differentiation of Tregs, proliferation inhibition, and apoptosis of T cells. a YM101 suppressed the differentiation of Tregs caused by TGF-β1. Murine splenocytes were treated with plated-coated CD3, CD28, IL-2, TGF-β1, and YM101 or controls. The results of flow cytometry showed the ratio of Treg in CD4 + T cells. b , c YM101 reversed the TGF-β1-caused proliferation inhibition in T cells. d YM101 counteracted the TGF-β1-caused alterations in cell cycle distribution in CTLL-2. e YM101 relieved the TGF-β1-mediated apoptosis in CTLL-2. f YM101 reversed the TGF-β1-caused alterations in cell cycle distribution in HT-2. g YM101 hedged the TGF-β1-mediated apoptosis in HT-2. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: YM101 counteracted TGF-β1-induced the differentiation of Tregs, proliferation inhibition, and apoptosis of T cells. a YM101 suppressed the differentiation of Tregs caused by TGF-β1. Murine splenocytes were treated with plated-coated CD3, CD28, IL-2, TGF-β1, and YM101 or controls. The results of flow cytometry showed the ratio of Treg in CD4 + T cells. b , c YM101 reversed the TGF-β1-caused proliferation inhibition in T cells. d YM101 counteracted the TGF-β1-caused alterations in cell cycle distribution in CTLL-2. e YM101 relieved the TGF-β1-mediated apoptosis in CTLL-2. f YM101 reversed the TGF-β1-caused alterations in cell cycle distribution in HT-2. g YM101 hedged the TGF-β1-mediated apoptosis in HT-2. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Inhibition, Flow Cytometry

YM101 antagonized the TGF-β1-caused changes in the cytokine release. a The heatmap showing the effects of TGF-β1 and YM101 on cytokine release during T cell activation. b – j YM101 reversed TGF-β1-mediated alterations in cytokine release including IL-2, IL-4, IL-5, IL-6, IL-9, IL-13, IL-22, TNF-α, and IL-17A. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: YM101 antagonized the TGF-β1-caused changes in the cytokine release. a The heatmap showing the effects of TGF-β1 and YM101 on cytokine release during T cell activation. b – j YM101 reversed TGF-β1-mediated alterations in cytokine release including IL-2, IL-4, IL-5, IL-6, IL-9, IL-13, IL-22, TNF-α, and IL-17A. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Activation Assay

YM101 counteracted the PD-1/PD-L1-mediated immunosuppression. a YM101 reversed the PD-1/PD-L1 axis-caused inhibition of IL-2 generation. The T cell activation assay was performed in the presence of exogeneous PD-L1 and YM101 or controls. b The CFSE dilution assays showed that YM101 antagonized the PD-1/PD-L1 axis-mediated proliferation inhibition in T cells. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: YM101 counteracted the PD-1/PD-L1-mediated immunosuppression. a YM101 reversed the PD-1/PD-L1 axis-caused inhibition of IL-2 generation. The T cell activation assay was performed in the presence of exogeneous PD-L1 and YM101 or controls. b The CFSE dilution assays showed that YM101 antagonized the PD-1/PD-L1 axis-mediated proliferation inhibition in T cells. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Inhibition, Activation Assay

YM101 treatment inhibited tumor growth in murine tumor models. a Exploring the optimal dosage of YM101 in the EMT-6 model. The growth curves of EMT-6 tumors of mice receiving different dosages of YM101. b The body weight change curves of EMT-6-bearing mice receiving different dosages of YM101. c The tumor images of EMT-6-bearing mice receiving the treatment of YM101 or controls. d The tumor growth curves of EMT-6-bearing mice receiving the treatment of YM101 or controls. e The tumor weights of EMT-6-bearing mice receiving the treatment of YM101 or controls. f The tumor images of CT26-bearing mice receiving the treatment of YM101 or controls. g The tumor growth curves of CT26-bearing mice receiving the treatment of YM101 or controls. h The tumor weights of CT26-bearing mice receiving the treatment of YM101 or controls. i The tumor images of 3LL-bearing mice receiving the treatment of YM101 or controls. j The tumor growth curves of 3LL-bearing mice receiving the treatment of YM101 or controls. k The tumor weights of 3LL-bearing mice receiving the treatment of YM101 or controls. l For the rechallenge assay, YM101-cured or treatment-naïve mice were inoculated with 1 × 10 6 3LL cells on the day 10 after the final YM101 injection. m The tumor images of the 3LL rechallenge assay. n The tumor growth curves of the 3LL rechallenge assay. o The tumor weights of the 3LL rechallenge assay. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1, CR: complete regression

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: YM101 treatment inhibited tumor growth in murine tumor models. a Exploring the optimal dosage of YM101 in the EMT-6 model. The growth curves of EMT-6 tumors of mice receiving different dosages of YM101. b The body weight change curves of EMT-6-bearing mice receiving different dosages of YM101. c The tumor images of EMT-6-bearing mice receiving the treatment of YM101 or controls. d The tumor growth curves of EMT-6-bearing mice receiving the treatment of YM101 or controls. e The tumor weights of EMT-6-bearing mice receiving the treatment of YM101 or controls. f The tumor images of CT26-bearing mice receiving the treatment of YM101 or controls. g The tumor growth curves of CT26-bearing mice receiving the treatment of YM101 or controls. h The tumor weights of CT26-bearing mice receiving the treatment of YM101 or controls. i The tumor images of 3LL-bearing mice receiving the treatment of YM101 or controls. j The tumor growth curves of 3LL-bearing mice receiving the treatment of YM101 or controls. k The tumor weights of 3LL-bearing mice receiving the treatment of YM101 or controls. l For the rechallenge assay, YM101-cured or treatment-naïve mice were inoculated with 1 × 10 6 3LL cells on the day 10 after the final YM101 injection. m The tumor images of the 3LL rechallenge assay. n The tumor growth curves of the 3LL rechallenge assay. o The tumor weights of the 3LL rechallenge assay. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1, CR: complete regression

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Injection

Immunohistochemical staining assays to measure the infiltration of T cells in EMT-6 tumors. a – d The presentative images of tumor-infiltrating CD3 + cells in the tumor periphery and the tumor center. Scale bars, 250 μm or 50 μm. e The quantitative analyses for the number of tumor-infiltrating CD3 + cells, and the proportion of CD3 + area was used. f The quantitative analysis for the infiltration depth. The infiltration depth of CD3 + cells was calculated by the mean nearest distance of all CD3 + cells to the tumor border. The mean nearest distance was scaled by the distance between the corresponding tumor border to tumor center. g , h The presentative images of tumor-infiltrating CD4 + and CD8 + cells in the tumor periphery and the tumor center. Scale bars, 100 μm. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: Immunohistochemical staining assays to measure the infiltration of T cells in EMT-6 tumors. a – d The presentative images of tumor-infiltrating CD3 + cells in the tumor periphery and the tumor center. Scale bars, 250 μm or 50 μm. e The quantitative analyses for the number of tumor-infiltrating CD3 + cells, and the proportion of CD3 + area was used. f The quantitative analysis for the infiltration depth. The infiltration depth of CD3 + cells was calculated by the mean nearest distance of all CD3 + cells to the tumor border. The mean nearest distance was scaled by the distance between the corresponding tumor border to tumor center. g , h The presentative images of tumor-infiltrating CD4 + and CD8 + cells in the tumor periphery and the tumor center. Scale bars, 100 μm. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Immunohistochemical staining, Staining

Flow cytometry assays to analyze the tumor immune microenvironment in EMT-6 tumors. Representative images of a tumor-infiltrating lymphocytes, b T cells, c granzyme B + T cells, d CD107a + T cells, e CD8 + T cells, f dendritic cells (DCs), g macrophages. The relative quantitative analysis was performed by the ratio of tumor-infiltrating immune cells to total alive cells in the prepared cell suspension. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: Flow cytometry assays to analyze the tumor immune microenvironment in EMT-6 tumors. Representative images of a tumor-infiltrating lymphocytes, b T cells, c granzyme B + T cells, d CD107a + T cells, e CD8 + T cells, f dendritic cells (DCs), g macrophages. The relative quantitative analysis was performed by the ratio of tumor-infiltrating immune cells to total alive cells in the prepared cell suspension. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Flow Cytometry

RNA-seq to explore the immune landscape of EMT-6 tumors. a The heat map of the expression levels of all differentially expressed genes (fold change > 2, p < 0.05). b The expression levels [The Reads Per Kilobase per Million mapped reads (RPKM)] of Prf1 , Ifng , Gzma , and Gzmb . c – h The expression levels of genes in T cell’s signature, NK’s signature, dendritic cell (DC)’s signature, macrophage’s signature, IFN-α response’s signature, IFN-γ response’s signature. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: RNA-seq to explore the immune landscape of EMT-6 tumors. a The heat map of the expression levels of all differentially expressed genes (fold change > 2, p < 0.05). b The expression levels [The Reads Per Kilobase per Million mapped reads (RPKM)] of Prf1 , Ifng , Gzma , and Gzmb . c – h The expression levels of genes in T cell’s signature, NK’s signature, dendritic cell (DC)’s signature, macrophage’s signature, IFN-α response’s signature, IFN-γ response’s signature. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: RNA Sequencing Assay, Expressing

Immunohistochemical staining to evaluate the activity of carcinoma-associated fibroblast, the status of mediated epithelial-mesenchymal transition of cancer cells, as well as the proliferation and apoptosis of cancer cells. a H&E staining. b Anti-α-SMA staining. c Picrosirius red staining. d Anti-E-cadherin staining. e Anti-Vimentin staining. f Anti-Ki-67 staining. g Anti-PCNA staining. h Anti-cleaved-Caspase 3. For quantitative analysis, the integral optical density (IOD) of values the IHC stainings were calculated. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. Scale bars, 100 μm. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: Immunohistochemical staining to evaluate the activity of carcinoma-associated fibroblast, the status of mediated epithelial-mesenchymal transition of cancer cells, as well as the proliferation and apoptosis of cancer cells. a H&E staining. b Anti-α-SMA staining. c Picrosirius red staining. d Anti-E-cadherin staining. e Anti-Vimentin staining. f Anti-Ki-67 staining. g Anti-PCNA staining. h Anti-cleaved-Caspase 3. For quantitative analysis, the integral optical density (IOD) of values the IHC stainings were calculated. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 denote the significant difference relative to YM101 treatment. Scale bars, 100 μm. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Immunohistochemical staining, Staining, Activity Assay

Schematic diagram showing the effect of YM101 on Cancer-Immunity Cycle and tumor cells. Firstly, YM101 promoted T cell infiltration by restraining the activity of carcinoma-associated fibroblast (CAF). Secondly, YM101 enhanced the tumor-killing activity of T cells by blocking PD-1/PD-L1 and naturalizing TGF-β. Thirdly, YM101 altered the polarization of macrophages and increased the ratio of M1/M2. Besides, YM101 increased the density of dendritic cells (DCs) which would be favorable to antigen presentation in the TME. Lastly, YM101 counteracted epithelial-mesenchymal transition (EMT) in tumor cells

Journal: Journal of Hematology & Oncology

Article Title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

doi: 10.1186/s13045-021-01045-x

Figure Lengend Snippet: Schematic diagram showing the effect of YM101 on Cancer-Immunity Cycle and tumor cells. Firstly, YM101 promoted T cell infiltration by restraining the activity of carcinoma-associated fibroblast (CAF). Secondly, YM101 enhanced the tumor-killing activity of T cells by blocking PD-1/PD-L1 and naturalizing TGF-β. Thirdly, YM101 altered the polarization of macrophages and increased the ratio of M1/M2. Besides, YM101 increased the density of dendritic cells (DCs) which would be favorable to antigen presentation in the TME. Lastly, YM101 counteracted epithelial-mesenchymal transition (EMT) in tumor cells

Article Snippet: 96 well flat-bottom plates (9018, Corning) were coated with TGF-β1 (Z03411, Genscript), TGF-β2 (Z03429, Genscript), TGF-β3 (Z03430, Genscript), and PD-L1 (50010-M03H, Sino Biological) (200 ng per well) at 4 °C overnight.

Techniques: Activity Assay, Blocking Assay